In this cohort study of 24 997 biologic exposures in 13 699 patients with psoriasis, risk of paradoxical eczema was lowest in patients receiving interleukin 23 inhibitors compared with other biologic classes. This evidence concerns the gene IL37 and Eczematoid dermatitis.